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The Role of Cytotoxic Therapy with Hematopoietic
Stem Cell Transplantation in the Treatment of
Multiple Myeloma
Among the primary objectives of the American
Society for Blood and Marrow Transplantation are to:
● Deﬁne commonly accepted medical practice
● Develop standards of medical care for autologous
and allogeneic transplants
● Provide recommendations and guidelines about
the role of transplantation as a therapeutic ap-
proach for reimbursement by third-party payers.
To this end, in 1999 the Society began the develop-
ment of evidence-based reviews of the scientiﬁc and
medical literature to document when blood and mar-
row transplantation is indicated in the treatment of
selected diseases.
Goals
The goals of the evidence-based reviews are to:
● Assemble and critically evaluate all of the evidence
regarding the role of cytotoxic therapy with he-
matopoietic stem cell transplantation in the treat-
ment of each disease selected for review
● Make treatment recommendations based on the
available evidence
● Identify discrepancies in study design or method-
ology among published studies that may impact
the quality of the evidence
● Identify needed areas of additional study
Guidelines
The following guidelines are offered for the role
of stem cell transplantation as therapy for multiple
myeloma and are based on consensus reached by an
expert panel1 following an evidence-based review of
the literature2:
1. Stem cell transplantation is more effective than
conventional chemotherapy as de novo therapy and
is the recommended treatment for patients requir-
ing treatment for multiple myeloma. Survival after
stem cell transplantation is equivalent for salvage
and de novo therapy. Stem cell transplantation as de
novo therapy is preferred, however, because it may
avoid the inconvenience, cost, and risk of myelo-
dysplasia from conventional alkylating agent ther-
apy.
2. Autologous stem cell transplantation is currently
the standard of care for multiple myeloma and is
preferred over allogeneic stem cell transplantation
based on available evidence. Studies are ongoing,
however, to further evaluate the role of allogeneic
transplant.
3. Autologous peripheral blood stem cell transplanta-
tion (PBSCT) is preferred over bone marrow
transplantation.
4. Autologous purged bone marrow transplantation is
not recommended as therapy for multiple my-
eloma.
5. Melphalan is preferred to melphalan plus total
body irradiation as the conditioning regimen for
autologous stem cell transplantation.
6. PBSCT using CD34 selected or CD34 unselected
stem cells are recommended as equivalent in efﬁ-
cacy.
7. No recommendations are made for transplantation
techniques that have not been adequately studied,
including:
● Stem cell transplantation versus standard che-
motherapy as salvage therapy
● Tandem autologous stem cell transplantation
● Autologous or allogeneic stem cell transplanta-
tion as a high-dose sequential regimen
● Allogeneic bone marrow transplantation versus
PBSCT
● A preferred allogeneic myeloablative or non-
myeloablative conditioning regimen
● Maintenance therapy post-autologous stem cell
transplantation
—Adopted by the ASBMT Executive Committee
on March 20, 2003
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1Expert panel members and authors of the review are: Theresa
Hahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; John
Wingard, MD, University of Florida College of Medicine, Gaines-
ville, FL; Kenneth C. Anderson, MD, Dana-Farber Cancer Insti-
tute, Harvard Medical School, Boston, MA; William I. Bensinger,
MD, Fred Hutchinson Cancer Research Center, Seattle, WA;
James R. Berenson, MD, Cedars Sinai Medical Center, Los Ange-
les, CA; Greg Brozeit, International Myeloma Foundation, Holly-
wood, CA; Joseph R. Carver, MD, Abramson Cancer Research
Institute, University of Pennsylvania, Philadelphia, PA; Robert A.
Kyle, MD, Mayo Clinic, Rochester, MN; and Philip L. McCarthy,
MD, Roswell Park Cancer Institute, Buffalo, NY.
2Reference: Hahn T, Wingard JR, Anderson KC, et al. The role of
cytotoxic therapy with hematopoietic stem cell transplantation in
the therapy of multiple myeloma: an evidence-based review. Biol
Blood Marrow Transplant. 2003;9:4-37.
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